Actinium Stock Forum

$Actinium (ATNM.US)$
Actinium Pharmaceuticals Announces Research Collaboration with Memorial Sloan Kettering to Support Further Clinical Expansion of Actimab-A's Backbone Therapy Strategy
Thursday, 20th March at 8:00 am
NEW YORK, March 20, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced that is has entered into a sponsored research agreement with Memorial Sloan Kettering Cancer...

$Actinium (ATNM.US)$
Actinium Unveils Massive Market Expansion: KOL to Present Breakthrough Cancer Therapy Progress

$Actinium (ATNM.US)$
Actinium's New Cancer Trial Combines Actimab-A With Blockbuster PD-1 Drugs - 500,000 Patient Opportunity

$Actinium (ATNM.US)$
Actinium Pharmaceuticals Announces Clinical Trial Program in Solid Tumors Combining Actimab-A with PD-1 Checkpoint Inhibitors KEYTRUDA® and OPDIVO®
Tuesday, 18th March at 8:00 am
- Trials are designed to demonstrate whether the addition of Actimab-A to either KEYTRUDA® or OPDIVO® can result in improved patient outcomes
- MDSCs – Myeloid Derived Suppressor Cells in the tumor microenvironment are believed to reduce effectiveness of PD-1 inhibitors like KEYTRUDA® and OPDIV...

$Actinium (ATNM.US)$
Actinium Pharmaceuticals Announces Publication of Actimab-A + CLAG-M Trial Results in Patients with Relapsed or Refractory Acute Myeloid Leukemia in the Peer-Reviewed Journal Leukemia
Monday, 17th March at 8:50 am
-       Median Overall Survival of 18.4 months with Actimab-A + CLAG-M in patients with relapsed or refractory AML who received 1 or 2 lines of prior therapy
-       Mutation agnostic potential of Actimab-A demonstrated by high rates of Complete Remissions and M...

$Actinium (ATNM.US)$
Revolutionary Triple-Drug Combination Trial Targets Newly Diagnosed AML Patients

$Actinium (ATNM.US)$ SECuRE Trial Update: 92% of Pre-chemo Participants Experience Greater Than 35% Drop in PSA Levels Across All Cohorts. Cohort Expansion Phase Commences.
PR Newswire
5 mins ago
HIGHLIGHTS
Safety Review Committee (SRC) meeting confirms end of the Dose Escalation Phase and commencement of the Cohort Expansion Phase (Phase II stage) of the SECuRE study.
Based on the efficacy and safety assessment of all cohorts and the focus on earlier stages of treatment, the SRC confirmed...

$Actinium (ATNM.US)$ NorthStar Medical Radioisotopes and YAP Therapeutics Enter Into Collaboration Agreement for the Development and Production of Radiopharmaceutical Products
Businesswire· 13 mins ago
NorthStar to support the development of YAP Therapeutics' innovative radiolabeled productsThis collaboration merges the expertise and resources from both companies, including NorthStar's state-of-the-art facilitiesThe agreement guarantees that YAP Therapeutics will receive clinical trial-read...

$Actinium (ATNM.US)$ SK Biopharmaceuticals Seals 1st Actinium-225-Based Collaborative Research Agreement With Korea Institute of Radiological and Medical Sciences as Steps Toward Becoming Global Radiopharmaceutical Therapy Player
PR Newswire· 10 mins ago
SK Biopharmaceuticals, Korea Institute of Radiological and Medical Sciences collaborate on discovering and developing radiopharmaceutical drug candidates using an alpha-particleemittingradioisotope, actinium-225, for potential cancer treatm...